Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$601.71 USD

601.71
1,081,605

+2.46 (0.41%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $601.55 -0.16 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Varian (VAR) Expands Presence With Germany's Ethos Order

Varian's (VAR) Ethos therapy is being adopted in Germany, thus expanding the company's geographic footprint.

The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific

The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific

Medtronic Receives FDA's Go Ahead for EFS Study on TTVR

Medtronic (MDT) begins the FDA-approved EFS of Intrepid TTVR system following the receipt of the Breakthrough Device Designation from the regulatory authority.

National Vision Banks on Contact Lens Sales Amid Coronavirus Woes

National Vision (EYE) sales bear the impact of unfavorable timing of unearned revenues.

Here's Why You Should Hold on to Medtronic Stock for Now

Investors continue to be optimistic about Medtronic (MDT) on robust segmental growth and strong ventilators sales.

Here's Why You Should Retain AmerisourceBergen Stock Now

AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches. However, stiff competition remains a woe.

Cerner (CERN) Inks Deal With Finland Regional Leadership

Cerner (CERN) collaborates with Finland regional leadership to help bring integrated health and care.

CHDN, AMC, FMS, OMI and TMO as Zacks Bull and Bear of the Day

CHDN, AMC, FMS, OMI and TMO as Zacks Bull and Bear of the Day

Varian Expands Access to Advanced Cancer Treatment With Ethos

Varian's (VAR) Ethos Therapy used by Goshen Center for Cancer Care marks the expansion access to personalized cancer care.

Urmimala Biswas headshot

Coronavirus Test Makers With Scope to Maximize Investor Benefits

The surge in new coronavirus infections broadens the scope for antigen and antibody tests.

Intersect ENT, AllianceRx Execute Pharmacy-Services Agreement

Intersect ENT (XENT) partners with AllianceRx to expand the access to SINUVA Sinus Implant.

Thermo Fisher Scientific (TMO) Gains As Market Dips: What You Should Know

In the latest trading session, Thermo Fisher Scientific (TMO) closed at $419.73, marking a +0.34% move from the previous day.

Henry Schein Partners MouthWatch to Grow in Teledentistry

Henry Schien's (HSIC) customer base is likely to benefit from the Teledent platform.

QIAGEN, Ellume Extend Alliance for COVID-19 Antigen Test

QIAGEN (QGEN) extends partnership with Ellume to offer the second COVID-19 test utilizing the latter's technology and strengthening its own COVID-19-testing portfolio.

Trina Mukherjee headshot

3 MedTech Outperformers to Grab Amid Coronavirus Pandemic

Let's grab these three stocks that have shown tremendous promise amid the coronavirus pandemic.

Is Thermo Fisher Scientific (TMO) Stock Outpacing Its Medical Peers This Year?

Is (TMO) Outperforming Other Medical Stocks This Year?

Abbott Banks on EPD, Nutrition Growth to Beat Coronavirus Woes

Abbott (ABT) expects to register strong growth for the second half of 2020 within established pharmaceuticals (EPD).

HealthEquity (HQY) Q2 Earnings and Revenues Beat Estimates

HealthEquity (HQY) witnessed strong growth in Service, Custodial and Interchange segments in Q2.

PRA Health (PRAH) Inks Deal With Leukemia & Lymphoma Society

PRA Health (PRAH) partners with LLS to bring new treatments for children with relapsed acute leukemia.

Bruker Banks on Strategic Innovation Amid Coronavirus Crisis

At Bruker's (BRKR) Germany campus, the company currently offers a pilot COVID-19 at work testing program for its factory workforce.

Henry Schein (HSIC) Enters Into New Dental Deal With Zyris

Henry Schien (HSIC) is set to be the exclusive distributor of Zyris products like Isolite 3, Isovac 2, Isodry and the company's patented single-use Mouthpieces.

Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio

Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

Nevro (NVRO) continues to gain traction from Senza, its flagship platform, and R&D capabilities. However, stiff competition remains a woe.

Varian's Halcyon System to Bring Improved Care to Singapore

Varian (VAR) strengthens its partnership Proton Therapy Pte as it brings improved care to Singapore through Halcyon system.

NextGen Healthcare Introduces New Behavioral Health Suite

NextGen Healthcare's (NXGN) new behavioral health suite aims to provide whole person care with support services for healthcare providers and clinicians.